Close menu




September 4th, 2024 | 07:30 CEST

Bayer, Vidac Pharma, BioNTech - Healthcare sector on the verge of a renaissance

  • Biotechnology
  • Biotech
  • Pharma
Photo credits: pixabay.com

Promising signs of a renaissance in the healthcare sector have emerged in recent months. Innovative start-ups are driving the digital transformation forward despite a decline in investment, as evidenced by the Digital Health Radar 2024. In Germany, Federal Health Minister Karl Lauterbach has introduced significant legislative reforms by July 2024, such as the introduction of electronic patient records and e-prescriptions. Complemented by increased M&A activity and technological integration through telehealth and AI, experts anticipate significant long-term growth potential despite the challenges faced in 2023. These developments point to a promising future for the healthcare sector. We take a look at three exciting candidates.

time to read: 4 minutes | Author: Armin Schulz
ISIN: BAYER AG NA O.N. | DE000BAY0017 , VIDAC PHARMA HOLDING PLC | GB00BM9XQ619 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    Bayer - Positive study results

    Bayer is still struggling with the legal disputes surrounding the expensive Monsanto takeover. In addition to the claims for damages, the resulting debts are weighing heavily on the Company. The Company is also facing challenges in oncology research. The start of the Phase III study "SOHO-2" for its potential lung cancer drug BAY2927088 is an important step. To date, there are no approved first-line targeted therapies for non-small cell lung cancer (NSCLC) with HER2 mutations. A successful trial is crucial for Bayer to strengthen the credibility of its pipeline and ensure long-term success in oncology. Competitive pressure and strict regulatory requirements present additional hurdles.

    Despite the challenges in the oncology field, Bayer is showing promising developments in its Pharmaceuticals division. The drug candidate Kerendia, already approved for treating chronic kidney disease in type 2 diabetes, could soon also be used for heart failure. Impressive results were presented at the ESC Cardiology Congress in London. The studies show a significant reduction in deaths and hospitalizations of 16% compared to placebo. This could enable an extension of the approval and secure Bayer a strong position in the cardiovascular drug market.

    Analysts see great potential in Bayer's recent advancements. The revenue increases achieved with Kerendia in the second quarter of this year underscore this: between April and June, Bayer recorded a 72% increase in revenue, reaching EUR 115 million. These figures reinforce investors' confidence in Bayer's ability to advance its pharmaceutical division despite existing challenges. If the approval of the extension remains successful, Kerendia could help to compensate for the lost revenue from other drugs with expiring patents. Analysts are forecasting peak annual sales of over EUR 2 billion for the drug. Bayer shares continue to trend sideways and are currently trading at EUR 28.15.

    Vidac Pharma - Technical report causes a stir

    Vidac Pharma, a listed company in the clinical development phase, offers an exciting and promising prospect. Vidac Pharma's latest product, VDA-1275, is at the center of interest following a technical report. This innovative drug candidate for the treatment of solid tumors has achieved impressive results in preclinical studies. As a monotherapy, VDA-1275 shows significant anti-tumor efficacy. Even more remarkable are the synergistic effects observed when VDA-1275 is used in combination with conventional cancer therapies. Another positive aspect is the ability of VDA-1275 to trigger an immune response - a promising indication of its potential in cancer treatment.

    The key findings of the study were that VDA-1275 restarts apoptosis (programmed cell death), stops the rapid proliferation of cancer cells, reduces the hyperglycolytic metabolism typical of tumors, triggers an immunological response, increases survival in a colon cancer model in mice in a statistically significant way, and shows a synergistic effect in combination with widely used anti-cancer drugs in a 3D organoid model of human liver cancer. The first human clinical trials are planned for Q1 2025. These tests mark a crucial step in the development of VDA-1275 and could catapult Vidac Pharma into a new era of cancer treatment options.

    Another promising product in the pipeline, VDA-1102, is already in Phase II clinical trials. This drug has already shown positive results in the treatment of actinic keratosis. In addition, regulatory authorities in Austria and Israel have given the green light for Phase II trials for the treatment of mycosis fungoides, a form of cutaneous T-cell lymphoma. In view of the progress made and the upcoming clinical trials, there is great potential here. The analysts at Sphene Capital issued a "Buy" recommendation with a target price of EUR 4.90 on July 29. The share is currently trading at EUR 0.25 in Stuttgart.

    BioNTech - From highs to challenges

    During the turbulent times of the COVID-19 pandemic, the biotech industry experienced an unprecedented boom, particularly due to the successful launch of mRNA vaccines. BioNTech was in the spotlight, posting record share prices and high profits. However, as the pandemic threat receded, the demand for vaccines also fell dramatically. The Company came under pressure to diversify its business models. However, the Mainz-based company does not yet have another product ready for series production and is, therefore, currently struggling with considerable losses and is forced to develop long-term growth strategies.

    After the pandemic, BioNTech increasingly focused on its roots: the development of cancer drugs. The Company is working on innovative therapies for infectious diseases such as malaria and tuberculosis as well as mRNA-based cancer vaccines. The hope is to use these technologies as successfully as with COVID-19. BioNTech's Chief Medical Officer Özlem Türeci recently stated that cancer therapy in the future will be personalized and targeted, with mRNA vaccines, antibody-drug conjugates, and cell therapies playing an important role.

    Despite the current losses and legal battles, such as patent disputes and demands for higher royalties, there are also bright spots. Successful research programs and the potential launch of new drugs could stabilize the share in the long term. Analysts expect a moderate recovery in the share price. Recent advances in oncology, combined with a focus on personalized medicine and targeted therapies, offer promising, albeit risky, investment potential in a changing biotechnology landscape. The share has now moved well away from the EUR 70 mark and is currently trading at EUR 78.85.


    Overall, everything points to a promising future for the healthcare sector. Despite challenges, Bayer is showing progress in the pharma sector, especially with Kerendia, which is showing significant clinical success. Vidac Pharma is achieving promising results in preclinical and clinical trials with innovative drugs such as VDA-1275 and VDA-1102 and is fully committed to the fight against cancer. BioNTech, on the other hand, is working hard to diversify its businesses, particularly in the field of cancer treatment**, to ensure long-term stability and growth. These developments point to a flourishing renaissance in the healthcare sector.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Armin Schulz on November 18th, 2026 | 05:30 CET

    Pharma Turnaround Stocks Under Review: Evotec, Vidac Pharma and Novo Nordisk – Restructuring, Clinical Trial Results and Outlook

    • Evotec
    • Vidac Pharma
    • Novo Nordisk
    • Drug discovery
    • Biotech
    • Pharma
    • Cancer
    • Oncology
    • Warburg effect
    • Obesity
    • Diabetes
    • Weight-loss pill

    Between November 4 and 9, three pharma and biotech stocks released news that suggests a turning point. At one, the quarterly loss before exceptional items narrowed; at the second, initial data from a placebo-controlled trial are available; and the third has raised its full-year guidance. These are not yet proof of a lasting turnaround, but they are verifiable signs of progress. If this trajectory can be maintained, hope could soon turn into substance. We therefore take a closer look at Evotec, Vidac Pharma and Novo Nordisk to see which has turnaround potential.

    Read

    Commented by Armin Schulz on November 17th, 2026 | 19:35 CET

    Bayer, Cardiol Therapeutics, Novartis – Biotech stocks and pharmaceutical giants in the race for the heart

    • Bayer
    • Cardiol Therapeutics
    • Novartis
    • Heart disease
    • Asundexian
    • Pharma
    • Pericarditis
    • CardiolRx
    • Leqvio

    Created and Published on Behalf of Cardiol Therapeutics

    Cardiology is one of the most exciting fields in the pharmaceutical industry. Four days in Chicago have shown just how much is happening in cardiovascular medicine. From November 6 to 9, pharmaceutical giants and small biotech companies gathered at the American Heart Association Scientific Sessions annual congress with a shared goal: to improve care for patients with cardiovascular disease. The major players bring experience and capital, while smaller companies often contribute fresh ideas. When a company succeeds in securing regulatory approval, investors stand to benefit. This interplay is precisely what makes the market so interesting for investors. We therefore take a closer look at Bayer, Cardiol Therapeutics, and Novartis.

    Read